165P Pathologic and immunohistochemical prognostic score in residual triple-negative breast cancer after neoadjuvant chemotherapy

Autor: S. Causeret, A. Hennequin, Isabelle Desmoulins, S.M. Ilie, C. Kaderbhai, Catherine Loustalot, Valentin Derangère, Sylvain Ladoire, Laurent Arnould, Charles Coutant, N. Briot, A. Ilie, Aurélie Bertaut

Publikováno v: Annals of Oncology. 32:S432

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::631fc87a93b5f04656e69ebf109a1040
https://doi.org/10.1016/j.annonc.2021.08.446

Surgery in reference centers improves survival of sarcoma patients: a nationwide study

Autor: A. Giraud, P. Soibinet, Sébastien Carrère, E. Stoeckle, G. Vaz, J. Guiramand, J.-C. Ruzic, A. Dufresne, Jean-Yves Blay, F. Gouin, A. Rochwerger, F. Duffaud, A. Le Cesne, Francis Guillemin, J.-P. Spano, M. Rios, P. Meeus, Isabelle Ray-Coquard, A. Di Marco, G. Ferron, François Bertucci, François Sirveaux, N. Firmin, F. Fiorenza, O. Collard, S. Bonvalot, Emmanuelle Bompas, S. Causeret, P. Anract, M. Jafari, D. Pérol, J.-C. Machiavello, O. Marco, F. Ducimetière, C. Honore, A. Italiano, A. Michot, M. Karanian-Philippe, Nicolas Penel, P. Gimbergues, Mickaël Ropars, M. Toulmonde, F. Marchal, M. Brahmi, C. Le Pechoux, L.R. Le Nail, C. Perrin, F. Le Loarer, C. Chevreau, A. Dupré, J.-M. Guilloit, L. Chaigneau, F. Dujardin

Publikováno v: Annals of Oncology
Annals of Oncology, 2019, Annals of oncology official journal of the European Society for Medical Oncology, 30 (7), pp.1143-1153. ⟨10.1093/annonc/mdz124⟩
Annals of Oncology, Elsevier, 2019, Annals of oncology official journal of the European Society for Medical Oncology, 30 (7), pp.1143-1153. ⟨10.1093/annonc/mdz124⟩

International audience; BackgroundNETSARC (netsarc.org) is a network of 26 sarcoma reference centers with specialized multidisciplinary tumor boards (MDTB) aiming to improve the outcome of sarcoma patients. Since 2010, presentation to an MDTB and exp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b54122cb3a85f728fd24f3f4bb19bd25
https://hal.science/hal-02509515/file/PIIS0923753419312323.pdf

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Correction to: Surgery in reference centers improves survival of sarcoma patients: a nationwide study

Autor: M. Karanian-Philippe, Isabelle Ray-Coquard, A. Di Marco, J.-M. Guilloit, C. Perrin, M. Toulmonde, J.-P. Spano, G. Ferron, C. Le Pechoux, O. Collard, M. Rios, François Sirveaux, J. Guiramand, A. Dufresne, L. Chaigneau, C. Chevreau, S. Causeret, P. Gimbergues, L.R. Le Nail, M. Jafari, J.-C. Ruzic, O. Marco, F. Gouin, G. Vaz, A. Dupré, P. Anract, E. Stoeckle, A. Michot, F. Dujardin, Jean-Yves Blay, Emmanuelle Bompas, F. Guillemin, C. Honore, F. Duffaud, P. Meeus, A. Rochwerger, Nicolas Penel, F. Fiorenza, F. Le Loarer, S. Bonvalot, Mickaël Ropars, A. Le Cesne, F. Ducimetière, D. Pérol, A. Italiano, F. Marchal, P. Soibinet, Sébastien Carrère, J.-C. Machiavello, A. Giraud, François Bertucci, N. Firmin, M. Brahmi

Publikováno v: Annals of Oncology
Annals of Oncology, Oxford University Press (OUP), 2019, 30 (8), pp.1407. ⟨10.1093/annonc/mdz170⟩

Background NETSARC (netsarc.org) is a network of 26 sarcoma reference centers with specialized multidisciplinary tumor boards (MDTB) aiming to improve the outcome of sarcoma patients. Since 2010, presentation to an MDTB and expert pathological review

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d02bc304ecfc6a0fa1b2e043fda3b81e
https://doi.org/10.1093/annonc/mdz170

Neoadjuvant therapy for breast cancer has no benefits on overall survival or on the mastectomy rate in routine clinical practice. A population-based study with a median follow-up of 11years using propensity score matching

Autor: Marc Bardou, Pierre Fumoleau, F. Bonnetain, Patrick Arveux, Laurent Arnould, Sandrine Dabakuyo, J. Fraisse, S. Causeret, Philippe Maingon, I. Le Ray, Gilles Créhange, Bruno Coudert

Publikováno v: European Journal of Cancer. 48:2300-2310

Background Even though neoadjuvant chemotherapy has shown no benefits on overall survival (OS), it is being widely used in the treatment of breast cancer. This is based on the assumption that it may diminish the mastectomy rate and therefore be clini

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fd87e0fd72e33b8a10d20d66d40ad1c
https://doi.org/10.1016/j.ejca.2012.03.020